ProQR Therapeutics (PRQR) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| B of A Securities | Initiated Coverage | Buy | $8.00 | Aug 20, 2026 |
| Evercore ISI Group | Maintained | Outperform | $6.00 from $5.00 | Jun 29, 2026 |
| Chardan Capital | Maintained | Buy | $3.00 from $4.00 | Jun 26, 2026 |
| Jones Trading | Maintained | Buy | $10.00 from $11.00 | Jun 26, 2026 |
| Chardan Capital | Maintained | Buy | $4.00 | Apr 9, 2026 |
| Chardan Capital | Maintained | Buy | $4.00 | Nov 4, 2025 |
| Chardan Capital | Maintained | Buy | $4.00 | Aug 8, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $8.00 | Jun 27, 2025 |
| JMP Securities | Maintained | Market Outperform | $8.00 | Jun 27, 2025 |
| Oppenheimer | Maintained | Outperform | $9.00 from $15.00 | May 13, 2025 |
| Evercore ISI Group | Initiated Coverage | Outperform | $5.00 | Apr 29, 2025 |
| Chardan Capital | Maintained | Buy | $4.00 | Mar 14, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 from $10.00 | Mar 14, 2025 |
| Jones Trading | Initiated Coverage | Buy | $11.00 | Feb 12, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Dec 12, 2024 |
| Chardan Capital | Maintained | Buy | $4.00 | Dec 12, 2024 |
| JMP Securities | Maintained | Market Outperform | $8.00 | Dec 12, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $5.00 | Nov 8, 2024 |
| Raymond James | Upgraded | Outperform → Strong Buy | $14.00 from $6.00 | Oct 29, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 | May 10, 2024 |
Frequently asked questions
What is the price target for PRQR stock?
The average 12-month analyst price target for ProQR Therapeutics (PRQR) is $6.75, with a high estimate of $10.00 and a low of $3.00, across 4 analysts.
Is PRQR a buy, sell, or hold?
Analysts covering ProQR Therapeutics currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for PRQR?
The average price target of $6.75 implies 216.90% upside from the last price of $2.13.
What is the latest analyst rating on PRQR?
On Aug 20, 2026, B of A Securities initiated coverage of ProQR Therapeutics at Buy with a price target of $8.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.